新闻通稿

主页/新闻通稿

Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines

The Oral Vaccine Successfully Produced Antibodies in a Preclinical Study After a Single Dose NEW YORK, March 19, 2021 /PRNewswire/ -- Good candidate for protection against COVID variants due to triple antigen targeting  Implications for potential ease of widescale distribution and administration anytime, anywhere for [...]

2021-03-19T08:40:00+00:00分类:新闻通稿|标签:|

Oramed Reaches 25% Randomization in World’s First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

ORA-D-013-1 study is recruiting 675 patients through 75 clinical sites throughout the U.S. NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled [...]

2021-03-16T08:25:00+00:00分类:新闻通稿|标签:|

Oramed Issues Letter to Shareholders

- Recruiting and Dosing Patients Across Growing Number of U.S. Sites in Phase 3 Oral Insulin Trial - Clinical Advancements in NASH & Leptin - Discussions with Potential Partners Under Way - To view a video message from the CEO, click here NEW YORK, Jan. [...]

2021-01-27T09:00:00+00:00分类:新闻通稿|标签:|

Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright BioConnect 2021 [...]

2021-01-07T08:40:00+00:00分类:新闻通稿|标签:|

Oramed Initiates Phase 2 NASH Trial of Oral Insulin

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in a global trial of its oral insulin capsule [...]

2020-12-02T08:25:00+00:00分类:新闻通稿|标签:|

Oramed Initiates Phase 3 Trial of Oral Insulin

NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened  the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 [...]

2020-11-24T08:10:00+00:00分类:新闻通稿|标签:|

Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar “Oral Delivery of Therapeutic Proteins – Oramed Story” on November 18, 2020

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific Officer Dr. Miriam  Kidron will join Premas [...]

2020-11-12T08:40:00+00:00分类:新闻通稿|标签:|